Janumet 50/500Mg Tablets 14S (Pack Size 2 X 7S)
Brand : obs pakistan pvt. ltd.
How it works
By increasing and prolonging active incretin levels, Sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner. It is a biguanide with antihyperglycemic effects, lowering both basal and postprandial plasma glucose. It does not stimulate insulin secretion and therefore does not produce hypoglycemia.
JANUMET TAB 50/500 MG 14'S
Requires Prescription (YES/NO)
It is indicated as: - Initial therapy in patients with type 2 diabetes mellitus to improve glycemic control when diet and exercise do not provide adequate glycemic control. As an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus inadequately controlled on Metformin HCl or Sitagliptin alone or in patients already being treated with the combination of Sitagliptin and Metformin HCl.
Common: nausea.Uncommon: somnolence, diarrhea, upper abdominal pain and blood glucose decreased.
When not to Use
The combination of Sitagliptin and Metformin HCl is contraindicated in:- Patients with type 1 diabetes. -Patients with known hypersensitivity to Sitagliptin, Metformin HCl or any other component of the product. - Acute or chronic metabolic acidosis , including ketoacidosis, with or without coma.
For patients with type 2 diabetes mellitus, whose hyperglycemic is inadequately controlled with diet and exercise alone, the recommended starting dose of (Sitagliptin + Metformin HCl) is 50mg of Sitagliptin + 500mg of Metformin HCl twice daily. Patients may be titrated upto 50mg Sitagliptin + 1000mg of Metformin HCl twice daily. The dosage of (Sitagliptin + Metformin HCl) should be individualized on the basis of patient’s current regimen, effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100mg Sitagliptin.
Storage yes or /no
Store this medicine at room temperature, away from direct light and heat.
Sitagliptin+Metformin HCl are known to be substantially excreted by the kidney.Metformin HCl-related lactic acidosis increases with the degree of insufficiency of renal function, therefore, serum creatinine concentrations should be determined regularly.
Since impaired hepatic function has been associated with some cases of lactic acidosis, Sitagliptin+Metformin HCl should generally be avoided in patients with clinical or laboratory evidence of hepatic disease.
Patient receiving Sitagliptin+Metformin HCl in combination with a sulphonylurea or with insulin may be at risk for hypoglycemia. Therefore, a reduction in the dose of the sulphonylurea or insulin may be necessary.
After initiation of Sitagliptin, patients should be observed carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, Sitagliptin should promptly be discontinued and appropriate management should be initiated.
Always consult your physician before using any medicine.
Digoxin , Furosemide , Nifedipine , Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine ranitidine, triamterene, trimethoprim, or vancomycin) , thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
syr bd 1cc insulin 6mm syringe 1s
disprin 300mg dispersible tablets 100s (pack size 10 x 10s)
panadol 500mg tablets 200s ( pack size 20x10s)